secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0000939767-24-000138
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis enters clinical collaboration with Merck for zanzalintinib combo trials in HNSCC and RCC
--------------------------------------------------------------------------------

- Collaboration covers zanzalintinib + KEYTRUDA in phase 3 HNSCC trial (STELLAR-305) and zanzalintinib + WELIREG in RCC phase 1/2 and two phase 3 trials.
- Merck supplies KEYTRUDA and sponsors one RCC phase 3; Exelixis co-funds phase 1/2 and other phase 3, supplies zanzalintinib and cabozantinib.
- Exelixis retains all global commercial and marketing rights to zanzalintinib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000138/0000939767-24-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000138/exel-20241014.htm
  HTML page:      https://secwatch.observer/filing/0000939767-24-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer